What we found on the web about Tasigna
Nilotinib - Wikipedia, the free encyclopedia
Nilotinib, in the form of the hydrochloride monohydrate salt, is a tyrosine kinase inhibitor. It inhibits BCR-ABL. [1] Uses. It was approved as Tasigna in the USA and the EU for ...
Tasigna Efficacy | Tasigna® (Nilotinib) International
Tasigna is a prescription medication used in the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) from Novartis Oncology. On this page ...
Pharmacy Medical Necessity Guidelines Tasigna® (nilotinib)
Pharmacy Medical Necessity Guidelines Tasigna ® (nilotinib) 1 of 4 Document ID#: 2119252 Subject: Tasigna (nilotinib) Effective Date: March 10, 2009 Clinical Documentation and ...
Media Releases - Novartis
Close: Print: 29/10/2007, 2007, 7.57 PM CET Tasigna® receives US approval providing new hope to chronic myeloid leukemia patients with resistance or intolerance to existing ...
The My Tasigna Connect Program
Welcome to the My Tasigna Connect Program. The My Tasigna Connect Program is provided to you and your Health Care Professional by Novartis Pharmaceuticals Corporation.
Nilotinib (Tasigna) - GIST Support
This page is for information related to Nilotinib (Tasigna) formerly called AMN107, one of the Clinical Trial Drugs. Feel free to add your own experiences with the drug in the ...
BRAND NAME Tasigna
Independent licensee of the Blue Cross and Blue Shield Association 1 Horizon BCBSNJ Medical Necessity Guideline Section Drugs Policy Number Effective Date 03/28/08 Review Date 9/26 ...
Tasigna - free medication information, such as ratings, side effects ...
Tasigna (Nilotinib) consumer rankings and reports, user rankings, generic equivalent, price level, conditions, effectiveness, side effects, ease to tolerate and use.
Tasigna Capsules (Nilotinib Capsules) Drug Information: Uses, Side ...
Learn about the prescription medication Tasigna Capsules (Nilotinib Capsules), drug uses, dosage, side effects, drug interactions, warnings, and patient labeling.
TASIGNA® (ta-sig-na)
1 TASIGNA ® (ta-sig-na) (nilotinib) Capsules Read this Medication Guide before you start taking Tasigna ® and each time you get a refill. There may be new information.
Nilotinib - Wikipedia, the free encyclopedia
Nilotinib, in the form of the hydrochloride monohydrate salt, is a tyrosine kinase inhibitor. It inhibits BCR-ABL. [1] Uses. It was approved as Tasigna in the USA and the EU for ...
Entry added by Creative Administrator
Creative Administrator also edited:
Here is what users have to say about Tasigna

Nilotinib, in the form of the hydrochloride monohydrate salt, is a tyrosine kinase inhibitor approved as Tasigna in the USA and the EU for drug-resistant chronic myelogenous leukemia (CML). In June 2006, a Phase I clinical trial found nilotinib, also known by its clinical code AMN107, has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor currently used as a first-line treatment. In that study 92% of patients (already resistant or unresponsive to Gleevec) achieved a normal white blood cell counts after 5 month of treatment.

Welcome to CWAnswers

CWAnswers is your guide to the sprawling world wide web. The directory aims to provide a useful guide made by users. You can share your knowledge as well - simply register and edit your first entry. For questions just contact the team at support - at - cwanswers.com.

Weblinks

Top 10

Things you find nowhere else.

Comments

You must be logged in to post a comment.

No comments yet on this topic. Be the first one!
These recent articles mention Tasigna
Switzerland Pharmaceuticals and Healthcare Report Q4 2009
PR Inside
... currencies, but declined 2% in US dollars to US$20.3bn. Pharmaceuticals delivered strong and sustained growth, with the division’s net sales rising by 12% in local currencies (+3% in US dollars) thanks to growth in the sales of Aclasta,...
Tasigna® shows rapid and deep responses in newly diagnosed patients ...
WebWire
* Phase II data demonstrate that Tasigna rapidly removes detectable cancer cells in 96% of patients at 12 months[1] * At 12 months, Tasigna also achieves a rapid and deep reduction of the abnormal protein that causes a life-threatening type...
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial ...
Redorbit.com
EAST HANOVER, N.J., Oct. 20 /PRNewswire/ -- Novartis announced today that Tasigna® (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec® (imatinib mesylate)...
Novartis drug Tasigna® meets primary endpoint in pivotal trial ...
WebWire
* Tasigna produced faster and deeper responses compared to Glivec as first-line treatment in Philadelphia chromosome-positive chronic myeloid leukemia * First registration study using molecular response as key indicator of patient outcomes;...
Drugmaker Novartis says quarterly profit up 1 percent, raises outlook
Silicon Valley
It noted that recently approved Lucentis, for patients with wet age-related macular degeneration, a form of blindness, and Tasigna, to treat certain forms of Philadelphia chromosome-positive chronic myeloid leukemia, compensated weakening p...
Novartis Says Tasigna Meets Endpoints Vs. Glivec In Late-stage ...
RTT News
(RTTNews) - Swiss drugmaker Novartis AG (NVS: News ) said Tuesday that its drug Tasigna met both primary and secondary goals in a pivotal trial against its leukemia drug Glivec as a first-line therapy in chronic myeloid leukemia, or CML, pa...